Thu, December 7, 2023
Wed, December 6, 2023
Tue, December 5, 2023
Mon, December 4, 2023
Fri, December 1, 2023
Thu, November 30, 2023

Jason Gerberry Initiated (ARWR) at Strong Buy and Held Target at $29 on, Dec 4th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. g-buy-and-held-target-at-29-on-dec-4th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Jason Gerberry of B of A Securities, Initiated "Arrowhead Pharmaceuticals, Inc." (ARWR) at Strong Buy and Held Target at $29 on, Dec 4th, 2023.

Jason has made no other calls on ARWR in the last 4 months.



There are 6 other peers that have a rating on ARWR. Out of the 6 peers that are also analyzing ARWR, 2 agree with Jason's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $37 on, Thursday, November 30th, 2023
  • Shawn Egan of "Citigroup" Initiated at Hold and Held Target at $33 on, Tuesday, September 19th, 2023


These are the ratings of the 4 analyists that currently disagree with Jason


  • Luca Issi of "RBC Capital" Reiterated at Buy and Held Target at $50 on, Thursday, November 30th, 2023
  • Patrick Trucchio of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $90 on, Wednesday, August 9th, 2023
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $47 on, Tuesday, August 8th, 2023
  • Keay Nakae of "Chardan Capital" Reiterated at Strong Buy and Held Target at $60 on, Tuesday, August 8th, 2023

Publication Contributing Sources